California-headquartered Vera Therapeutics has appointed Dr. Celia Lin as Chief Medicial Officer.
Vera Therapeutics, a clinical stage biotech focused on developing and commercializing treatments for immunological diseases. Its lead program is atacicept, a fusion protein that is in development for IgA nephropathy.
The company welcomes Dr. Lin’s extensive clinical and industry experience in orphan diseases and multiple therapeutic areas, including nephrology and inflammation.
Dr. Lin’s previous role was as a Senior Medical Director at Genentech, where she was responsible for Phase III global study execution and regulatory filing in an orphan disease. She also was the global development lead for a small molecule in multiple sclerosis and led other projects, including monoclonal antibodies, bispecifics, and complement inhibition assets in various therapeutic areas such as respiratory, allergy, nephrology, infectious disease, and inflammation.
Prior to Genentech, she was a medical director in clinical development and medical affairs at Amgen: where she led teams and activities related to the approval and commercialization of two osteoporosis therapies.
Dr. Lin is board certified in internal medicine and rheumatology. Prior to joining industry, she was on faculty at the University of California, San Francisco (UCSF) seeing patients at the San Francisco Veterans Affairs Health Care System. She received her MD from the University of Rochester School of Medicine and a BS from the University of California, Los Angeles (UCLA). She trained in internal medicine at Boston Medical Center and in rheumatology at UCLA and Washington University in St. Louis where she also was a post-doctoral fellow.
In addition, Vera Therapeutics has appointed Tad Thomas, PhD, as Senior Vice President (SVP) and Head of Product Development and Manufacturing; and Joseph Young, MBA, as SVP of Finance.